Grifols SA Signals Stable Margins, Strong IG Growth

Grifols SA ((GRFS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Grifols SA’s latest earnings call struck an overall upbeat tone, as management balanced robust Biopharma growth, stable margins and tighter cost control against a handful of manageable headwinds. Executives stressed that currency effects, albumin softness in China and some access frictions were temporary, while structural moves in plasma sourcing, debt reduction and diagnostics platforms underpin a stronger medium‑term outlook.

Revenue Growth Holds Despite FX Drag

Grifols reported first‑quarter 2026 revenues of EUR 1.7 billion, representing 3.3% growth at constant currency versus last year. Management underscored that reported figures were dampened by euro strength, but underlying demand trends in core franchises remained healthy across major geographies.

Margins Steady With Adjusted EBITDA Resilience

Adjusted EBITDA came in at EUR 381 million, or EUR 404 million at constant currency, keeping margins broadly stable at 22.4%. Despite currency translation pressure, adjusted EBITDA grew 0.8% at constant exchange rates, highlighting the company’s ability to protect profitability as volumes and mix evolve.

Biopharma Momentum Driven by Immunoglobulins

Biopharma revenues rose 6.8% at constant currency, with immunoglobulins the clear standout. IG sales jumped 15.3% year on year, fueled by continued Gamunex strength and strong double‑digit demand for Xembify, which management expects will maintain robust double‑digit growth for the full year.

Profits Climb Despite Currency Headwinds

Group profit increased 22% year over year to EUR 73 million in the quarter, reflecting improved operational efficiency and mix. Management emphasized that this bottom‑line progress came despite adverse FX translation, pointing to underlying earnings quality and discipline.

Cost Discipline Supports Margin Preservation

Operating expenses fell 7.7% at constant currency versus the prior‑year quarter, providing a key lever for margin resilience. The company highlighted ongoing efficiency programs and tight cost controls as central to offsetting inflation and funding growth investments.

Balance Sheet De‑Risking and Liquidity Boost

Net leverage improved to 4.3 times, down 0.2 turns year over year, as Grifols continued to de‑risk its capital structure. The firm refinanced upcoming maturities, extended and upsized its revolving credit facility to more than USD 2 billion with a 6.5‑year tenor, reducing refinancing risk until late 2028.

Credit Profile Strengthened by Bond Actions

Grifols executed a partial redemption of EUR 500 million 7.5% bonds, helped by strong investor appetite, which in turn enabled structural enhancements to its debt stack. Two of the three major rating agencies have now upgraded the company back into the BB category, signaling improved market confidence.

Egyptian Plasma Strategy Targets Lower Costs

The European regulator approved plasma sourced from Egypt, marking a strategic inflection for Grifols’ supply chain. The company aims to collect around 1 million liters in Egypt in 2026, scaling to approximately 3 million liters by 2029, which should lift ex‑U.S. plasma volumes 2.5 times and support lower cost per liter over time.

Diagnostics Pivot to New Platforms

On a like‑for‑like basis, Diagnostics revenue grew in the low single digits, even as the dissolution of a legacy joint venture weighed on reported figures. Management highlighted upcoming launches of the Barcelona Next Generation blood‑typing system in the second quarter and the ISARD immunoassay platform, which should expand the segment’s addressable market.

Network Optimization to Lift Productivity

Grifols is closing or optimizing 29 underperforming donor centers in the U.S., consolidating volumes into more efficient locations. The company expects this network reshaping to enhance plasma quality, lower cost per liter and support margins without requiring significant additional capital expenditure.

Albumin Pressure in China Set to Persist Near Term

Albumin revenues fell 6.1% at constant currency as China faced pricing pressure, elevated inventories and price adjustments implemented in mid‑2025. Management guided to continued weakness versus last year through the first half, with expectations for market normalization and stabilization into the second half of 2026.

Alpha‑1 and Specialty Proteins Underperform

Alpha‑1 and specialty proteins revenue declined 7.4% year on year, reflecting a tough comparison that included prior‑year inventory buy‑ins. Additional softness in fibrin sealant and Factor VIII, plus access and re‑authorization hurdles in the U.S., added pressure to these smaller but strategically relevant categories.

Diagnostics Reported Decline Masks Underlying Growth

Reported Diagnostics sales declined due to the unwinding of the Quidel Ortho joint business, creating a mechanical headwind in the segment. However, Grifols stressed that like‑for‑like revenues still grew modestly and pointed to agreed compensation payments over three years as partial offset to the reported shortfall.

Seasonal Free Cash Flow Weakness Moderates

Free cash flow before M&A was negative EUR 8 million in the quarter, a seasonal pattern tied to working capital needs and inventory build. Even so, this represented an improvement of around EUR 30 million versus the same period last year, suggesting incremental progress toward structurally stronger cash generation.

FX Translation Dampens Reported Growth

The weakening of the U.S. dollar, with the EUR/USD average moving from 1.04 to 1.18 year on year, weighed on reported revenue and EBITDA in euro terms. Management noted that some of this impact is mitigated further down the income statement, but acknowledged that FX remains a notable swing factor for investors monitoring headline growth.

Bio Supplies Variability from Contract Phasing

Revenues from Bio Supplies and related activities were softer in the quarter, driven largely by timing of contracts and spot transactions. Management expects this segment to catch up in the third and fourth quarters, but cautioned that it will continue to introduce some quarterly volatility into consolidated results.

Market Access Challenges in Key Regions

The company is experiencing access issues in the U.S., including re‑authorization intervals affecting Alpha‑1 patients, alongside competitive and pricing pressures in certain markets. Management signaled that albumin and some specialty lines may remain under pressure in the first half, while ongoing pricing and access initiatives aim to restore momentum later in the year.

Strategic Transaction Uncertainty Weighs on Visibility

Grifols disclosed that it is evaluating an initial public offering of a portion of its U.S. Biopharma business but provided no further details. The lack of additional commentary leaves investors with limited visibility on timing or structure, adding an element of uncertainty to the otherwise constructive strategic narrative.

Outlook and Guidance Reinforce Constructive Trajectory

Management reaffirmed 2026 targets of an adjusted EBITDA margin of at least 25% and adjusted EBITDA growth of 5–9% at constant currency, alongside improving free cash flow toward EUR 500–575 million. Executives expect continued IG strength, a ramp in Egyptian plasma, and disciplined costs to drive margin expansion, while balance sheet actions help keep cash interest at or below 2025 levels.

Grifols’ earnings call painted a picture of a company leaning into its strengths while actively managing its weak spots. Investors will be watching for proof that plasma sourcing in Egypt, IG growth and cost discipline can fully offset areas like Chinese albumin and FX drag, but the overall tone and reaffirmed guidance suggest management sees more tailwinds than headwinds ahead.